17 May 2023
How to optimise peri-PCI antiplatelet treatment in clinical practice? Novel evidence on cangrelor
Sponsored by Chiesi Farmaceutici
Anchorperson:
G.G. Toth
Spokesperson:
D. Angiolillo
Summary
Discover the optimal approach to peri-percutaneous coronary intervention (PCI) antiplatelet treatment in clinical practice with a focus on the novel agent cangrelor. Gain a deeper understanding of the rationale behind cangrelor's use in various PCI settings, learn about the current recommendations and practices for its administration in both acute and elective PCI procedures and stay up to date with the latest real-world evidence from European registries on its efficacy and safety.
Learning Objectives
- To understand the rationale for the use of cangrelor across different PCI settings
- To learn current recommendations and practices of cangrelor use in acute and elective PCI
- To know the latest real-world evidence from European registries on cangrelor
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)
/slide017.jpg)
/slide018.jpg)
/slide019.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)
/slide017.jpg)
/slide018.jpg)
/slide019.jpg)
/slide020.jpg)